Clinical Scorecard: PsA Treatment Options Expand
At a Glance
| Category | Detail |
|---|---|
| Condition | Active Psoriatic Arthritis (PsA) |
| Key Mechanisms | Deucravacitinib is a selective TYK2 inhibitor targeting interleukin-23, interleukin-12, and type 1 interferon pathways. |
| Target Population | Adults aged 18 years or older with active PsA and a history of plaque psoriasis. |
| Care Setting | Multicenter, randomized, double-blind, placebo-controlled clinical trials. |
Key Highlights
- Deucravacitinib is the first TYK2 inhibitor approved for PsA.
- Improved ACR20 response rates: 54% vs 34% (POETYK PsA-1) and 54% vs 39% (POETYK PsA-2).
- ACR50 and ACR70 responses also favored deucravacitinib.
- Minimal disease activity achieved by a greater proportion of patients on deucravacitinib.
- Safety profile consistent with previous studies in plaque psoriasis.
Guideline-Based Recommendations
Diagnosis
- Diagnosis based on clinical criteria including swollen and tender joints, and history of plaque psoriasis.
Management
- Consider deucravacitinib for adults with active PsA, especially those with prior TNF inhibitor exposure.
Monitoring & Follow-up
- Monitor for common adverse reactions such as upper respiratory infections and increased creatine phosphokinase.
Risks
- Potential adverse reactions include herpes simplex, mouth ulcers, folliculitis, and acne.
Patient & Prescribing Data
Adults with active PsA, including those with prior TNF inhibitor exposure.
Deucravacitinib is administered once daily at a dose of 6 mg.
Clinical Best Practices
- Utilize ACR20 criteria for assessing treatment response.
- Consider patient history of biologic DMARDs when prescribing.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
